1. The use of 4-anilino-3-cyanoquinoline compounds selected from neratinib, bosutinib and erlotinib, and capecitabine in the combined treatment regimen of the neoplasm. ! 2. The treatment regimen according to claim 1, wherein the neoplasm is breast cancer. ! 3. The treatment regimen of claim 1, wherein the breast cancer is selected from Erb-2 positive metastatic breast cancer and locally advanced breast cancer. ! 4. The treatment regimen according to claim 1, wherein the neoplasm is an Erb-2 positive solid tumor. ! 5. The treatment regimen according to claim 1, where one or both active components are proposed in a subtherapeutically effective amount. ! 6. The treatment regimen of claim 1, wherein the 4-anilino-3-cyanoquinoline compound and capecitabine are delivered orally. ! 7. The treatment regimen according to claim 1, wherein the 4-anilino-3-cyanoquinoline compound and capecitabine are administered simultaneously sequentially, separately, in the indicated order or in accordance with specific time relationships. ! 8. The treatment regimen according to claim 1, wherein the 4-anilino-3-cyanoquinoline compound is administered in a single dose. ! 9. The treatment regimen according to claim 1, wherein said capecitabine compound is administered in a single dose. ! 10. The treatment regimen of claim 1, wherein capecitabine is administered in an amount of about 1250 mg to about 3000 mg per day. ! 11. The treatment regimen according to any one of claims 1 to 10, wherein capecitabine is administered at least once for 21 days. ! 12. The treatment regimen according to claim 11, wherein the capecitabine administration regimen lasts from 3 to 6 cycles. ! 13. The treatment regimen of claim 1, wherein HKI-272 is administered in an amount of at least about 40 mg. ! 14. The treatment regimen of claim 13, wherein HKI-272 is administered in an amount of at least about 120 mg. ! 15. The treatment regimen of claim 14, wherein HKI-272 is administered in a1. Применение 4-анилино-3-циано
